Modified RNAs as potential drug targets

• Autorzy: Guenther R. , Forrest B. , Newman W. , Malkiewicz A. , Agris P.F.
• Języki publikacji: EN

Abstrakty

EN

Bleomycin (BLM) is a natural antibiotic that is effective in treatment of selected cancers. Although the exact therapeutic mechanism of bleomycin is not known, its target is thought to be a nucleic acid. Besides cleaving DNA, in vitro, Fe-bleomycin cleaves the anticodon of yeast tRNAPhe specifically. Using CD and fluorescence spectroscopy we have found that apo-bleomycin binds to synthetic RNA analogs of the anticodon of yeast tRNAPhe with an affinity similar to that previously reported for DNA. In order to understand BLM's selectivity, the role magnesium ions play in RNA recognition should be explained. Many RNA substrates for Fe-BLM, including yeast tRNAPhe, are not cleaved by the drug when the Mg2+ concentration exceeds 1 mM. Competition experiments with anticodon analogs provide insight into the role of magnesium ions in RNA recognition by BLM. These simple modified RNAs may be useful as model systems for investigating BLM/RNA recognition and development of highly selective drugs toward RNA targets.

Słowa kluczowe

EN

tRNAPhe; fluorescence; modified RNA; drug target; antibiotic; cancer; oligonucleotide; bleomycin

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1998
• Tom: 45
• Numer: 1
• Opis fizyczny: p.13-18,fig.

Twórcy

autor

Guenther R.

• North Carolina, State University, Raleigh NC 27695, USA

autor

Forrest B.

autor

Newman W.

autor

Malkiewicz A.

autor

Agris P.F.

Bibliografia

• 1. Umezawa, H., Maeda, K., Takeuchi, T. & Okami, Y. (1966) New antibiotics, bleomycin A and B. J. Antibiot. 19,200-209.
• 2. Blum, R.H., Carter. S.K. & Agre, K. (1973) A clinical review of bleomycin — a new antineo­plastic agent Cancer 31, 903-914.
• 3. Stubbe, J. & Kozarich, J.W. (1987) Mecha­nisms of bleomycin-induced DNA degrada­tion. Chem. Rev. 87, 1107-1136.
• 4. Morgan. M.A. & Hecht, S.M. (1994) Iron (II) bleomycin-mediated degradation of a DNA- RNA heteroduplex. Biochemistry 33, 10286- 10293.
• 5. Holmes, C.E., Carter, B.J. & Hecht, S.M. (1993) Characterization of iron (ID'bleomy­cin- mediated RNA strand scission. Biochemis­try 32,4293-4307.
• 6. Holmes, C.E. & Hecht, S.M. (1993) Fe • Bleomycin cleaves a transfer RNA precursor and its "transfer DNA" analog at the same ma­jor site. J. Biol Chem. 268, 25909-25913.
• 7. Huttenhofer, A., Hudson, S., Noller, H.F. & Mascharak, P.K. (1992) Cleavage of tRNA by FedD-bleomycin. J. Biol Chem. 267, 24471- 24475.
• 8. Agris, P.F. (1996) The importance of being modified: Roles of modified nucleosides and Mg2* in RNA structure and function. Prog. Nu­cleic Acid Res. Mol. Biol 53, 79-129.
• 9. Agris, P.F., Malkiewicz, A., Krasewski, A., Ev­erett, K., Nawrot, B., Sochacka, E., Jan- kowska, J. & Guenther, R. (1995) Site-selected introduction of modified purine and pyrimid- ine ribonucleosides into RNA by automated phosphoramidite chemistry. Biochimie 77, 125-134.
• 10. Chen, Y., Sierzputowska-Gracz, H., Guenther, R., Everett, K. & Agris, P.F. (1993) 5- Methylcytidine is required for cooperative binding of Mg2* and a conformational transi­tion at the anticodon stem-loop of yeast phen-ylalanine tRNA. Biochemistry 32, 10249- 10253.
• ll.Chien, M., Grollman, A.P. & Horwitz, S.B. (1977) Bleomycin-DNA interactions: Fluores­cence and proton magnetic resonance studies. Biochemistry 16, 3641-3647.
• 12.Xu, R.X., Nettesheim, D., Otvos, J.O. & Peter­ing, D.H. (1994) NMR determination of the structures of peroxycobalt (111) bleomycin and cobalt (III) bleomycin, products of the aerobic oxidation of cobalt (II) bleomycin by dioxygen. Biochemistry 33, 907-916.